Impact de la tomographie par émission de positons au 18fluorodésoxyglucose dans la prise en charge des cancers de primitif inconnu

Aim and methodThis retrospective study, performed on 37 patients, gave us the opportunity to evaluate the impact of ¹⁸F-FDG PET/CT for cancer of unknown primary (CUP). We first wanted to study the precision of the exam to detect the primary, after a negative check-up, for the extension of the disease, and to judge the impact of the results on management and survival of those patients.ResultThe PET/CT led to the detection of the primary for 14 patients out of 37, after a negative check-up composed of five exams on average. For 10 patients, the exam allows the detection of supplementary metastases. The management was changed after the exam in more than one third of the patients, but without any significant impact on the time of survival of these patients, for whom the prognostic is usually dismal.ConclusionThe ¹⁸F-FDG PET/CT appears a valuable tool for detection of primary, changing the management of many of the patients. These results must be completed by a prospective study, in particular to judge the impact of exam's results on the survival.     

Cancer thyroïdien de souche folliculaire avec persistance d’anticorps antithyroglobuline : signification pronostique et apport de la TEP/TDM au F-FDG

Aim

To investigate the rate of persistence or/and recurrence of follicular cell-derived thyroid cancer with elevated serum antithyroglobulin antibody (TgAb) one year after ablative therapy. We also evaluated the predictive factors of persistence or/and recurrence and the clinical impact of PET/CT with FDG.

Methods

This retrospective study involved 154 TgAb+ patients. PET/CT was performed in 22 patients with a pejorative anatomo-clinical type. The results of the PET/CT were compared with histology and clinical follow-up.

Results

In 23 cases, thyroglobulin (Tg) was positive (14% of TgAb+ Tg+) while in other 131 cases, stimulated Tg was negative (86% of TgAb+ Tg−). Twenty-nine patients (18%) were finally diagnosed with persistent or recurrent disease during follow-up. Independent predictive factors were: age higher than 60 years, Tg+, increase of TgAb concentration in the first year following surgery, and T3/T4/N1 status. PET/CT showed sensitivity of 66% and specificity of 90%. Positivity of PET/CT was significantly associated with a poor prognosis.

Discussion and conclusion

There is no significant association between persistence of TgAb and persistent/recurrent disease when stimulated Tg is negative. An increase of TgAb concentration in the first year of follow-up is an important prognostic indicator. PET/CT with FDG seems to be very useful in the therapeutic management of differentiated thyroid cancer, especially for the patients with pejorative anatomo-clinical types.     

Tomographie par émission de positons au F-fluorodeoxyglucose dans la mise en évidence de la maladie veineuse thromboembolique

Purpose

Association of venous thromboembolism (VTE) and inflammation reported in the literature may allow the use of FDG PET/CT in the detection of thrombotic process. Published studies remain limited and contradictory. The aim was, therefore, to evaluate the performance of FDG PET/CT for the detection of VTE.

Patients and methods

Patients included in a prospective study evaluating FDG PET/CT for the detection of malignancy in patients with idiopathic VTE were analysed (MVTEP, PHRC 2008). PET/CT images were interpreted initially without and then retrospectively with knowledge of VTE locations.

Results

Hundred and fourteen patients were included in MVTEP study from March 13th 2009 to July 1st 2010. Forty-six patients (median age: 74 years [20-87], 27 males, 19 females) were analysed. No abnormal uptake was initially reported in pulmonary vessels. The retrospective analysis of pulmonary embolism locations did not demonstrate any significant difference in FDG uptake between embolic sites and controlateral vessels (P = 0.883). Initial analysis of lower limbs vessels demonstrated sensitivity and specificity of PET/CT for deep venous thrombosis (DVT) diagnosis of 15 and 99%. The metabolic activity of DVT was significantly higher than the activity of controlateral vessels (P < 0.005) but without showing any significant SUV threshold for DVT diagnosis.

Conclusion

In conclusion, there is insufficient evidence to suggest that FDG PET/CT could be accurate in detection of VTE. These results need to be completed in a larger study with shorter delay between VTE and FDG PET/CT.     

Intérêt de la TEP/TDM au FDG dans l’investigation étiologique des syndromes paranéoplasiques

Paraneoplastic syndromes (PNS) represent a rare and heterogeneous group of entities whose clinical symptoms may sometimes antedate the diagnosis of the causative tumor. In the context, the identification of the underlying tumor becomes very important for the patient's functional and sometimes vital prognosis, by allowing an earliest treatment of the tumor. ¹⁸FDG PET/CT has become indispensable in the diagnosis and follow-up of numerous cancers but its role in etiological investigation of isolated paraneoplastic syndromes for the research of an occult tumor is not defined yet. Nevertheless, requests of PET/CT in this indication are frequent in nuclear medicine departments, with an uncertain diagnostic yield. We have listed retrospectively 64 patients, sent to nuclear medicine department of Nancy university hospital between 2004 and 2010 for the research of an occult tumor because of a clinically suspected paraneoplastic syndrome, in order to estimate its diagnostic contribution in this indication. According to our results, ¹⁸FDG PET-CT would be interesting by its negative predictive value concerning the tumoral risk, in keeping with its known sensitivity PET-CT may also present an interest for the diagnosis and the characterization of non-tumoral conditions generating symptoms initially wrongly suspected to be paraneoplastic.     

Comparaison de la dose efficace en TEP/TDM et en TDM

Hybrid imaging, particularly positron emission tomography (PET) combined with CT has emerged in the field of oncology as a modality of choice. The concomitant realization of a standard CT examination, however, raises the question of the additional dose delivered to the patient. This radiation burden could be avoided by performing a single PET/CT examination with injection of contrast media. To verify the potential dosimetric gain of this strategy, we compared the effective dose associated with each modality in a retrospective cohort of 151 patients, homogeneous in weight and size. The average effective dose for a PET/CT (injection of 5-6 MBq/kg of ¹⁸FDG) was 13.5 mSv, the CT dose representing approximately 80% of the PET dose. In our study, the average effective dose in CT thorax/abdomen/pelvis was 21.4 mSv, 60% higher than the PET/CT effective dose.     

Metformin May Be Associated with False-Negative Cancer Detection in the Gastrointestinal Tract on Pet/Ct

ObjectiveConcurrent therapy with the antihyperglycemic drug metformin can hinder the detection of malignancy in the abdominal and pelvic portions of ¹⁸F-fluordeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging performed for the diagnosis or staging of malignancy, as well as for treatment response and radiation therapy planning. This is due to the metformin-induced increase in intestinal FDG radiotracer uptake. We aim to bring this potentially important interaction to the attention of clinicians who care for cancer patients with diabetes.MethodsWe searched MEDLINE (from 1970 to January 2014)and Google Scholar for relevant English-language articles using the following search terms: “metformin and FDG/PET, metformin and bowel uptake, metformin, and cancer, metformin and the intestine, metformin pharmacokinetics, hyperglycemia and FDG/PET.” We reviewed the reference lists of pertinent articles with respect to metformin gut physiology, impact on FDG uptake and the effect on diagnostic accuracy of abdominal-pelvic PET/CT scans with concurrent metformin therapy.ResultsWe reviewed the action of metformin in the intestine, with particular emphasis on the role of metformin in PET/CT imaging and include a discussion of clinical studies on the topic to help refine knowledge and inform practice. Finally, we discuss aspects pertinent to the management of type 2 diabetes (T2D) patients on metformin undergoing PET/CT.ConclusionsMetformin leads to intense, diffusely increased FDG uptake in the colon, and to a lesser degree, the small intestine, which limits the diagnostic capabilities of FDG PET/CT scanning and may mask gastrointestinal malignancies. We suggest that metformin be discontinued 48 hours before FDG PET/CT scanning is performed in oncology patients. More rigorous data are needed to support the widespread generalizability of this recommendation. (Endocr Pract. 2014;20:1079-1083)     

Apport d’un nouveau score visuel en TEP/TDM au 18Fluorodeoxyglucose (18FDG) lors des récidives ganglionnaires de cancer ORL après traitement initial

New visual score in PET/CT 18Fluorodeoxyglucose (¹⁸FDG) to evaluate lymph node recurrence of head and neck cancer after initial treatment. Neck dissection for node recurrence of head and neck cancer is known for important morbidity after initial radiation therapy. ¹⁸FDG PET/CT in this situation looks interesting but needs standardized interpretation. Our objective was to develop a PET/CT interpretation method in suspicious locoregional head and neck recurrence. Twenty-seven patients with suspicious lymph node recurrence after initial radiation ± chemotherapy for head and neck cancer were retrospectively included. ¹⁸FDG PET/CT was performed before neck dissection and histological data. Initial PET records, binary visual scale, five-point visual scale “Deauville like” and semi-quantitative index were assessed by 2 reviewers. A lymph node recurrence was confirmed in 19 patients (70%) based on histological results. PET records analysis found 6 false positive (FP), 2 true negative (TN) and 19 true positive (TP), with a sensibility (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) of 100%, 25%, 76% and 100%, respectively. Binary visual scale reclassified 1/6 FP. “Deauville like” criteria, reclassified 4/6 FP with the first reviewer (P < 0.001) and 5/6 with the second (P < 0.002), improving Sp and PPV of 66% and 95%, respectively. Kappa concordance coefficient for “Deauville like” scale was 0.88. Semi-quantitative index like SUVmax, SUVmean, SUVpeak, MTV, TLG and SAM showed no statistical value. Those preliminary results warrant a standardized visual scale, particularly the “Deauville like” criteria for ¹⁸FDG PET/CT interpretation in suspected lymph node recurrence of head and neck cancer.     

La fluorocholine(18F) a une utilité clinique dans le cancer de la prostate et le carcinome hépatocellulaire… parfois chez le même malade

Case reportIn order to stage hepatocellular carcinoma (HCC), a patient was referred to PET/CT using fluorodeoxyglucose(18F) (FDG) and, if necessary, fluorocholine(18F) (FCH). HCC was proven by biopsy of a hepatic mass discovered on CT performed for a biological recurrence of prostate cancer.ResultFDG PET/CT did not show any anomaly. FCH PET/CT was thus performed and showed various foci: the hepatic mass, a large abdominal adenopathy and an unexpected subcentimetre lung nodule. The diagnostic uncertainty mostly concerned this lung nodule which was biopsied and consisted of a metastasis of the prostate cancer. Due to the presence of two metastatic cancers, the patient's management was altered, with chemotherapy for the HCC and hormone therapy for the prostate cancer.ConclusionSeveral types of cancer take-up fluorocholine(18F), which is a powerful tool to detect metastases, in particular in case of rising levels of marker with a negative FDG PET/CT. Even when FDG PET/CT is positive, FCH may reveal unexpected foci with other metabolic characteristics, although it is not specific of a given primary cancer, as well as FDG. For staging of HCC, we thus recommend to perform PET/CT with both tracers.     

La fixation vasculaire du 18FDG est reliée au risque d’événements récents ou futurs chez les patients à haut risque cardiovasculaire

With this study, we sought to identify plaque inflammation as assessed by ¹⁸FDG uptake on positron emission tomography (PET)/computed tomography (CT) as an independent cardiovascular risk factor in patients at high risk for cardiovascular events. We compared 31 consecutive cancer patients presenting with visually enhanced ¹⁸FDG uptake in arterial walls on PET/CT (Group 1) to a selection of 34 matched cancer patients not showing arterial uptake (Group 2). All patients were followed for two years before and six months after PET/CT… Cardiovascular events were classified as older (>6 months before PET/CT) or recent (<6 months before or after PET/CT). ¹⁸FDG uptake was computed on non-attenuation corrected data by a AW/L ratio: mean Arterial Wall uptake/Lung uptake in a normal area, and by SUV on corrected data. A calcium score (CS) was also calculated. ¹⁸FDG uptake and CS were higher in Group 1 than Group 2 (both p = 0.02), and older and recent cardiovascular events were significantly more frequent in Group 1 than Group 2 (p = 0.001 and p = 0.03, respectively). Among the following parameters: number of conventional risk factor, calcium score and presence of ¹⁸FDG uptake, only the latter was significantly related to the occurrence of a recent event by multivariate analysis (p = 0.02). Patients with elevated arterial ¹⁸FDG uptake have a high risk of immediate or future cardiovascular events. Arterial ¹⁸FDG uptake is an indicator of evolving atherosclerotic process and can indicate future cardiovascular events.     

Intérêt de la TEP/TDM au 18FDG dans les sous-types histologiques agressifs de cancers thyroïdiens (oncocytaire et peu différencié)

IntroductionThe objective of our study was to evaluate the performance of ¹⁸FDG PET/CT in aggressive histological subtypes of differentiated cancer of the thyroid and its therapeutic impact.MethodThirty-three patients (22 Hürthle cell carcinoma and 11 poorly differentiated carcinoma) who underwent FDG PET/CT were retrospectively included. Nine scans have been performed for initial staging, 16 for suspicion of recurrence (with 11 having a rising Tg), 3 for the reassessment of metastatic disease under systemic treatment and 30 systematically during follow-up. The results of PET/CT were confronted with histological data and follow-up results.ResultsThirteen out of 18 positive scans were confirmed (8 locoregional recurrences and 5 distant metastases). The majority of them were performed for a suspicion of recurrence (8) or for initial staging (2). The sensitivity, specificity, PPV, and NPV were respectively 81.2%, 88.1%, 72.2% and 92.5%. For Hürthle cell carcinoma and poorly differentiated carcinoma, the sensitivity and specificity were respectively 100% vs. 57% and 86% vs. 93%. Systematic PET scans were most of the time negative (26/30) and in accordance with histological and follow-up results. It was the same in case of scans performed for undetectable initial Tg (16/22). PET/CT modified patient management in 14% of the cases.ConclusionThis study confirms the good performances of ¹⁸FDG PET/CT for initial staging and in case of elevated Tg during the follow-up of aggressive histological subtypes of thyroid cancer. It does not seem relevant in the absence of a suspicion of recurrence or in the case of undetectable initial Tg.     

Thromboses néoplasiques et thromboses cruoriques mécaniques compliquant un cancer du testicule gauche en TEP/TDM au 18FDG

We report the case of a 46-year-old patient with pulmonary embolism complicating thrombosis of the left renal vein and inferior vena cava, which came from a malignant tumor of the left testicle. The case has been elucidated by positron emission tomography with ¹⁸FDG coupled to the CT-scan (PET/CT), performed as part of the etiological assessment of this pulmonary embolism, and anatomical and physiological considerations. The examination revealed ¹⁸FDG uptake in thrombus of the left kidney vein and the inferior vena cava. In view of the anatomy of the left spermatic vein, this finding led to the left testicle, which shows no nuclide uptake but was bathed in a large hydrocele visible on CT images. If several cases of pulmonary embolism or thrombosis of the inferior vena cava revealing a testicular cancer have been described in the literature, there has been no report including ¹⁸FDG PET/CT to the best of our knowledge. This case illustrates the imaging differences between bland and malignant thrombus as a consequence of their pathophysiology. It highlights the contribution of CT images from the PET/CT for the diagnosis.     

Effet du traitement par pegfilgrastim sur la fixation de la fluorocholine (18F) par la moelle osseuse

This patient had been treated by radical prostatectomy for adenocarcinoma. Fifteen years later, he was referred to us due to occult biochemical recurrence (PSA = 1.56 ng/mL). Fluoride (18F) PET/CT and then fluorocholine (18F) (FCH) PET/CT were performed. On fluoride (18F) PET/CT, only one focus in the left iliac crest was suspicious but the biopsy of an osteoblastic anomaly had been performed 5 months before, with a negative result. On FCH PET/CT, a diffuse and intense uptake of bone marrow was noted, as well as a focus corresponding to a right external iliac lymph node, which had already been visualised on the previous FCH PET/CT and prompted endoscopic resection of three lymph nodes, which proved to be non-malignant. The osteomedullary uptake was attributed to a very recent treatment by pegfilgrastim, a recombinant human granulocyte colony stimulating factor (G-CSF). It was concluded that the recurrence was electively located in this lymphatic basin and IMRT was performed which led to a fourfold reduction in PSA serum levels. This observation illustrates the risk, never mentioned yet, of false-positive results concerning osteomedullary cancer spread, in case of treatment by G-CSF. It also confirms the role of FCH PET/CT in case of occult recurrence of prostate cancer, including verification of resection of a suspicious lymph node detected on a previous FCH PET/CT, and its capacity to guide IMRT.     

Impact de la TEP/TDM au 18F-FDG dans la prise en charge des patients atteints de cancer thyroïdien différencié

Aim¹⁸F-FDG PET/CT by combining both metabolic and anatomical informations has proven to be an effective modality for detecting many types of cancer. Some differentiated forms of cancer like differentiated thyroid carcinoma (DTC) are less FDG avid and thus less easily detectable. Nevertheless ¹⁸F-FDG PET/CT has been proved useful in DTC especially in case of suspected recurrent disease with negative whole-body radioiodine scintigraphy (¹³¹I WBS) and elevated thyroglobulin (Tg) or thyroglobulin autoantibodies (AbTg) levels. Impact on clinical management after ¹⁸F-FDG PET/CT examinations has been analyzed in patients with suspected recurrent DTC in this retrospective study.MethodologyFifty-five ¹⁸F-FDG PET/CT were performed in 45 patients with suspected recurrent or residual disease either because of elevated Tg/AbTg levels (n = 45) or uncertain conventional imaging (n = 10) including ¹³¹I WBS, cervical echography and CT scan if necessary. ¹⁸F-FDG PET/CT results were compared with histopatology and/or clinical follow-up with evaluation of impact on clinical management.ResultsTwenty-nine exams were positive (53 %). There were 20 true-positive (TP) (14 locoregional relapses and six with distant metastases) and nine false-positive (FP) (all cervical). SUV_max median values of hypermetabolic foci were significantly higher in TP (5.1) than in FP (2.8). Overall, 20 (36 %) ¹⁸F-FDG PET/CT directly affected clinical management resulting in 13 (65 %) new surgical operations. Sensitivity, specificity, predictive positive value, predictive negative value and accuracy of ¹⁸F-FDG PET/CT were estimated for the whole group (respectively 83 %, 71 %, 69 %, 85 % and 76 %) and for two subgroups depending on Tg level (less or more than 1.2 ng/mL).Discussion and conclusion¹⁸F-FDG PET/CT is a powerful and useful tool in patients with suspected DTC recurrence or residual disease and should be systematically performed when basal Tg level is above 1.2 ng/mL. Thanks to given anatomical informations it can guide surgical re-operation.     

Récidive biologique de cancer de la prostate : intérêt de la TEP/TDM à la fluorocholine (18F) du corps entier

Case reportA patient was referred to fluorocholine (18F) PET/CT to restage a biological recurrence of his prostate cancer. There was a doubt on local and lymph node recurrence on MRI.ResultPET/CT showed several pelvic foci evocative of local and lymph node recurrence, more extensive than the MRI anomaly without bone lesion; this recurrence was treated by hormone therapy. But FCH PET/CT also revealed a left cerebral focus. Cerebral MRI was therefore performed which confirmed an anomaly evocative of a grade II brain lesion.ConclusionThis observation illustrates the fact that, in case of prostate cancer, a whole-body imaging, including the skull, is useful, even when foci are detected in the pelvis. Several types of cancer take-up fluorocholine (18F): in case of a visceral distant focus in a patient with prostate cancer, the hypothesis of a second primary cancer should be considered.     

Embolie pulmonaire de découverte fortuite en TEP/TDM au 18F-fluorodésoxyglucose avec injection de produit de contraste iodé réalisée dans un contexte oncologique : à propos de trois cas cliniques

We report three cases of incidentally detected pulmonary embolism in oncologic ¹⁸F-FDG PET/CT scans. These pulmonary embolisms, without significant uptake of ¹⁸F-FDG, would not have been depicted without the contribution of contrast enhanced CT scans on an integrated PET/CT system. These three cases are contradictory to already published data describing focal uptake of ¹⁸F-FDG corresponding to thrombi.     

TEP/TDM au fluorure (18F) de sodium pour la détection des métastases osseuses du cancer de la prostate. Description de l’étude Fluprostic de comparaison de la TEP/TDM au fluorure (18F) de sodium à l’IRM corps entier dans cette indication

Fluorodeoxyglucose (¹⁸F) or FDG, the radioactive glucose analogue which is the reference radiopharmaceutical in oncologic PET, is not well suited for the detection of prostate cancer metastases the glucose metabolism of which is usually only slightly enhanced. Fluoride (¹⁸F) accumulates into the cortical bone, rapidly and intensely in reaction to a bony metastasis. In 2008, it has been granted a marketing authorisation in France, including imaging bone metastasis of prostate cancer. We report original clinical cases to illustrate its diagnostic performance. Whole-body MRI is developing and can also detect bone metastases. Recently diffusion-weighted MRI (DWI) has been proposed to increase the detection rate of metastases of the axial skeleton, which are largely predominant in prostate cancer. Using either hybrid PET/CT or MRI requires mobilising equipments, which are less available and more expensive than the gamma-cameras for classical bone scintigraphy, in the aim to achieve superior diagnostic performance. A clinical study protocol (STIC) has just been accepted for public funding. It aims to assess the impact on patient management of the discovery of the first macroscopic bony metastasis and the efficacy of diagnostic strategies including those innovations, individually and in association. In case of prostate cancer with a high risk of metastasis, but without any proven bone metastasis and no typical pattern on bone scintigraphy, fluoride (¹⁸F) PET/CT will be performed as well as whole-body MRI. Histopathology and/or data of a 6-month follow-up will be the standard of truth to evaluate the adequacy of impact on patient management and the benefit / cost ratio of those examinations. With this prospective national study, we hope to demonstrate in the real world a clinical role for this radiopharmaceutical, which was proposed several decades ago, but benefits from a renewed interest thanks to the development of PET/CT imaging.     

La TEP/TDM au FDG a-t-elle un impact dans la prise en charge des patients atteints d’un cancer du canal anal ?

PurposeTo evaluate the impact of FDG PET/CT on the management of patients referred for the staging and/or the follow-up of anal carcinoma, and PET/CT on patient management.Patients and methodsWe included patients referred to our department for anal carcinoma whose therapeutic management was evaluable thanks to follow-up data during at least 6 months.ResultsData of 44 patients were analysed: 22 had PET/CT for initial staging and 36 during follow-up. PET/CT had impact in nine patients out of 44 (20%) and it was relevant in eight of them.ConclusionFDG PET/CT is an accurate imaging modality in anal cancer, its impact on patient management is more obvious when persistence or recurrence of disease is suspected.     

Intérêt de la tomographie par émission de positons (TEP) au 18FDG dans le suivi des patients traités pour carcinome épidermoïde des voies aérodigestives supérieures (VADS) en rémission clinique

IntroductionPosttreatment follow-up of head and neck squamous cell carcinoma (HNSCC) recurrence is a diagnostic challenge. Tissue distortions from radiation and surgery can obscure early detection of recurrence by conventional follow-up approaches such as physical examination (PE), computed tomography, and magnetic resonance imaging. A number of studies have shown that ¹⁸Fluoro-fluorodeoxyglucose (¹⁸FDG) Positron emission tomography (PET) may be an effective technique for the detection of persistent, recurrent, and distant metastatic HNSCC after treatment. The aim of this prospective study was to determine the benefits (sensitivity, specificity, predictive values, and accuracy) of ¹⁸FDG PET using hybrid PET–Computed tomography system (PET/CT) in the detection of HNSCC subclinical locoregional recurrence and distant metastases, in patients 12 months after curative treatment with a negative conventional follow up.Materials and MethodsNinety-one patients cured from head and neck squamous cell carcinoma (HNSCC) without any clinical element for recurrence were included. Whole-body ¹⁸FDG PET/CT examination was performed 11.6 ± 4.4 months after the end of the treatment. The gold standard was histopathology or 6 months imaging follow-up.ResultsThe whole-body ¹⁸FDG PET/CT of the 91 patients in this study consisted of 52 negative and 39 positive results. Nine of these patients who exhibited abnormal ¹⁸FDG uptake in head and neck area did not have subsequently proven recurrent HNSCC (false positive). Thirty had proven recurrence (true positive). All 52 patients with negative readings of ¹⁸FDG PET/CT remained free of disease at 6 months (true negative). The sensitivity and specificity of ¹⁸FDG PET/CT in this study for the diagnosis of HNSCC recurrence were 100% (30/30) and 85% (52/61) respectively. The positive predictive value was 77% (30/39). The negative predictive value was 100% (52/52). The overall accuracy was 90% (82/91).ConclusionThe results of our study confirm the high effectiveness of ¹⁸FDG PET/CT in assessment of HNSCC recurrence. It suggests that this modality is more accurate than conventional follow-up PE alone in the assessment of patient recurrence after previous curative treatment for HNSCC. Therefore, a PET study could be systematically proposed at 12 months after the end of the treatment.     

Comparison of 68GA-FAPI-04 PET/CT and 18F-FDG PET/CT in detection of metastatic bone disease in various cancers

ObjectiveOur aim in this retrospective study was to compare the diagnostic accuracy of ⁶⁸Ga-FAPI-04 PET/CT and ¹⁸F-FDG PET/CT in detecting bone metastases of various cancers and to evaluate the potential usefulness of ⁶⁸Ga-FAPI-04 PET/CT in detecting metastatic bone disease.Material and methodOur retrospective study included 44 patients diagnosed with bone metastases due to various cancers between January 2021 and February 2022. All patients underwent ⁶⁸Ga-FAPI-04 PET/CT and ¹⁸F-FDG PET/CT imaging within 14 days. In the semi-quantitative analysis of the skeletal system, all regions with higher uptake than background activity were considered pathological. SUVmax and Metastasis-to-background ratio (TBR) values were calculated from metastatic sites.ResultsA total of 827 bone metastases were detected in our study. The diagnostic accuracies of FAPI PET/CT and ¹⁸F-FDG PET/CT were 91.8% and 81.5%, respectively (P < 0.001). When all bone metastases were compared, the SUVmax of ⁶⁸Ga-FAPI-04 PET/CT was statistically significantly higher than that of ¹⁸F-FDG PET/CT (median 6.15 vs. 5.2; P < 0.001). When FDG and FAPI SUVmax values were compared according to metastasis types, FAPI SUVmax and TBR values in osteolytic, medullary and mixed type bone metastases were found to be statistically significantly higher than FDG (P-values: < 0.001, < 0.001, < 0.001, respectively). There was no statistically significant difference between FDG and FAPI SUVmax values in osteoblastic bone metastases (P = 0.26).ConclusionIt has been shown that ⁶⁸Ga-FAPI-04 PET/CT is superior to ¹⁸F-FDG PET/CT in detecting metastatic bone disease and may have more clinical impact on disease management.     

Identification of Metabolic Biomarkers Using Serial 18F–FDG PET/CT for Prediction of Recurrence in Advanced Epithelial Ovarian Cancer

PURPOSE. To evaluate the prognostic value of metabolic parameters derived from serial ¹⁸F fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in patients with advanced epithelial ovarian cancer (EOC). METHODS. Thirteen patients with advanced EOC who received surgical staging and adjuvant platinum-based combination chemotherapy were prospectively enrolled. ¹⁸F–FDG PET/CT was performed before and after the surgical staging, and after third cycle of chemotherapy. Tumor glucose metabolism at baseline and its change after operation and third cycle of chemotherapy such as changes of maximum standardized uptake values (ΔSUV_max) via ¹⁸F–FDG PET/CT were measured, and assessed regarding their ability to predict recurrence. RESULTS. Median duration of progression-free survival (PFS) was 25 months (range, 13–34), and although optimal debulking was performed in 10 patients, 5 (38.5%) patients experienced recurrence. Univariate analyses showed significant associations between recurrence and low ΔSUV_max after surgical staging, and low SUV_max change after third cycle of chemotherapy. Multivariate analysis identified low ΔSUV_max after third cycle of chemotherapy as an independent risk factor for recurrence (P = .047, hazard ratio (HR) 16.375, 95% CI 1.041–257.536). Kaplan–Meier survival curves showed that PFS significantly differed in groups categorized based on ΔSUV_max after chemotherapy (P = .001, log-rank test). CONCLUSIONS. ¹⁸F–FDG PET/CT allows for prediction of treatment response by the level of FDG uptake in terms of SUV at baseline and after chemotherapy. The metabolic response measured as ΔSUV_max after third cycle of chemotherapy appears to be promising predictor of recurrence in patients with advanced EOC.